The Driehaus US Growth Equities team focuses on investing in US-listed equities of public companies with market capitalizations between $100 million and $15 billion, through the Driehaus Micro Cap Growth, Driehaus Small Cap Growth, Driehaus Small/Mid Cap Growth and Driehaus Life Sciences strategies. The strategies provide investors with high active share portfolios of companies experiencing positive fundamental changes in addition to exposure to positive growth inflections, earnings surprises and earnings revisions, factors that are positively correlated to alpha generation. The team is led by Jeff James who began his portfolio management career at Driehaus in 1998. He is supported by seven analysts that combined have over 50 years of Driehaus research experience.
Our institutional sales team will be pleased to address questions and requests related to separately managed accounts and/or institutional commingled vehicles that employ our investment strategies.
Ask Us!The strategy seeks to outperform the Russell Microcap® Growth Index over full market cycles.
The strategy seeks to outperform the Russell 2000® Growth Index over full market cycles.
The strategy seeks to outperform the Russell 2500® Growth Index over full market cycles.
The strategy intends to exploit the inefficiencies in how markets assign risk to development-stage and early-commercial stage healthcare companies.
The team employs a growth-oriented investment philosophy focusing on identifying company-specific growth inflection points and exploiting associated marketplace inefficiencies. Core to the philosophy are the beliefs that: earnings are the primary driver of equity prices over time, market expectations tend to be ‘anchored’ to historical information and points of inflection therefore introduce dislocations between market expectations and fundamentals which generate significant alpha capture opportunities. The team combines fundamental, macro/sector/industry and behavioral analysis in its investment process together with a nimble/active investment approach to quickly identify inefficiencies and generate a portfolio, which uniquely seeks to achieve superior aggregate growth rates as well as superior risk characteristics.
Generative artificial intelligence (GenAI) has been one of the hottest topics in the investment community this year, at times getting even more attention than the Fed and its battle with inflation. One prominent software executive recently called it the most important technology ever. Its impact on stocks has been significant, especially in the technology sector where stocks deemed as beneficiaries of GenAI have meaningfully outperformed this year while those perceived as being threatened have severely lagged. With several billions of dollars already being spent or committed for building out GenAI infrastructure, there are questions emerging about the practical uses for GenAI and the extent to which there will be business cases and financial models that can justify the enormous investments being made
One prominent theme from the June 2023 quarter earnings season is the return of normal business seasonality. The pandemic disrupted supply chains all over the world, and as we move away from that period lead times continue to normalize. In many cases, lead times have improved from over a year to only a few months.